A recent article in Genetic Engineering and Biotech News, found here, discusses the necessity of and options for improved biospecimen tracking, procurement, and distribution that extends beyond biobanks alone. The authors emphasize the importance of rich analytical biospecimen data, dynamic sample collection, and efficient sample distribution. With the ultimate goal to propel biobanking forward in order to efficiently support the advancement of personalized medicine, frozen aliquotting technology’s ability to preserve biospecimen integrity and increase utilization is key to this goal.
Integrating data from tissue imaging, genomic databases, and clinical results could be a major key in the journey toward truly personalized medicine, according to a recent article in Genetic Engineering and Biotechnology News (found here). Careful maintenance of patient data correlated with tissue samples is one element of the best practices necessary for a truly integrated data approach to drug discovery and development.
Biopreservation and Biobanking published an article in their June edition that offers an alternative for data analysis and disclosure for biobanks. Outlined here, authors Kuiper, van den Heuvel and Swertz argue for a data analysis model that addresses privacy control issues while allowing for greater access to usable information for the support of valuable research efforts using their Statistical Disclosure Control model. This approach steps outside the more traditional methods of suppression and obfuscation.
An article appearing in R and D Magazine (found here) echoes CryoXtract’s call for careful and consistent procedures for sample handling and maintenance at biobanks. Without thoughtful attention to process and temperature controls, sample integrity can be compromised which can negatively impact critical research in the life sciences field.
Last week, CryoXtract presented two posters at the 2015 annual meeting of the International Society for Biological and Environmental Repositories (ISBER) in Phoenix, AZ. The meeting’s theme, “Connecting Biobank Communities through Innovations in Global Health, Research and Environmental Preservation,” featured symposia on topics ranging from biobanking informatics and infrastructure to community engagement.
In a recent interview with Dr. Peng Wang, Chief Executive Officer of the Beijing Biobank of Clinical Resources at Capital Medical University (CMU), ISBER President Andy Zaayenga discussed the history and key facets of the Chinese biobanking industry. With 15 clinical-based biobanks, the CMU network is now in phase two of its development and houses approximately 100,000 cases for major disease research.
The Chinese biobank system is a large network consisting of biobanks from several major Chinese hospitals. Through strict maintenance of its central database and bioinformatics network, CMU promotes unified standards across sites and emphasizes the critical importance of maintaining sample integrity and output.
The rapidly growing CMU biobank network is financially supported by the Beijing Municipal Science and Technology Committee, and its samples target research in major diseases including cardiovascular and cerebrovascular diseases, metabolic diseases such as diabetes, and cancer. Information on collection sizes and scope is available to researchers and the public on the biobank’s website, which promotes sharing and utilization of these valuable specimens throughout China.
Dr. Wang, who led the establishment of the clinical biobank for PUMC hospital in 2009, says each biobank in the system reports collecting 150-1500 samples each week. “With the rapid increase in prevalence of major diseases within the Chinese population, the financial burden of patient treatment is growing,” said Dr. Wang. “Finding a way to improve diagnosis and treatment options for these patients is a critical task for the medical society.”
Furthermore, the biobanking movement in China is responding to the increasing global emphasis on translational medical research. The population’s relatively large sample pool offers a tremendous resource for medical researchers across the globe, potentially reducing sample collection timelines. The industry's promising developmental trajectory does face hurdles, however. Implementing unified quality control and evaluation programs and harmonizing a collaborative sample sharing system are key elements of success.
To read the interview transcript, click here.
The annual conference of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB), held in Leipzig last month set forth a theme entitled, “A Chorale Symphony of Science, Technology and Human Rights,” and provided a lineup of presentations that discussed new initiatives and technology advances in biobanking.
At last month’s annual conference of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) in Leipzig, Germany, CryoXtract presented a poster on using frozen aliquotting for the preservation of analytical profiles in neurodegenerative research. The poster, entitled “Preserving Analytical Profiles of CNS Samples for Neurodegenerative Disease Research using Frozen Aliquotting Sample Handling Technology,” detailed potential improvements in sample processing techniques for central nervous system (CNS) disease tissue and biofluids biospecimens.
Freeze-thaw damage to highly sensitive CNS biospecimens can dramatically hinder the growing amount of research in the fields of neurodegenerative disease. By integrating frozen aliquotting into modern neurobiological research, greater access to high quality annotated CNS samples could yield improved diagnostic and treatment options for the growing populations facing diseases such as Alzheimer's and Parkinson's.
CryoXtract Instruments is excited to be presenting two posters and a display booth at the annual conference of the European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB) that starts tomorrow in Leipzig, Germany.
Audio and transcript of Interview between Larry Chin, Vice President of Business Development for CryoXtract, and Dr. Cathie Miller, Global Product Manager for Biobanking and Chromatography for WHEATON® Industries